Urinary α1-Antichymotrypsin as a Biomarker for Prion Infection
Author Information
Author(s): Miele Gino, Seeger Harald, Marino Denis, Eberhard Ralf, Heikenwalder Mathias, Stoeck Katharina, Basagni Max, Knight Richard, Green Alison, Chianini Francesca, Wüthrich Rudolf P., Hock Christoph, Zerr Inga, Aguzzi Adriano
Primary Institution: Department of Pathology, UniversitätsSpital Zürich, Institute of Neuropathology, Zürich, Switzerland
Hypothesis
Can urinary α1-antichymotrypsin levels serve as a biomarker for prion disease diagnosis?
Conclusion
The study found that urinary α1-antichymotrypsin levels are significantly elevated in patients with sporadic Creutzfeldt-Jakob disease, suggesting its potential as a biomarker for monitoring the disease.
Supporting Evidence
- Urinary α1-antichymotrypsin levels were significantly higher in sCJD patients compared to controls.
- The study found a progressive increase in urinary α1-antichymotrypsin levels throughout the clinical course of disease.
- ROC curve analysis indicated high sensitivity and specificity for urinary α1-antichymotrypsin in diagnosing sCJD.
Takeaway
This study shows that a protein called α1-antichymotrypsin in urine can help doctors find out if someone has a brain disease caused by prions.
Methodology
The researchers analyzed urine samples from patients with sporadic Creutzfeldt-Jakob disease and compared them to control groups, measuring levels of α1-antichymotrypsin using ELISA.
Potential Biases
Potential bias in sample selection as patients with known renal issues were excluded.
Limitations
The study did not assess the long-term stability of urinary α1-antichymotrypsin levels over time.
Participant Demographics
Patients included those with sporadic Creutzfeldt-Jakob disease, Alzheimer's disease, and healthy controls, matched for age and gender.
Statistical Information
P-Value
0.019
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website